Pulmonx

General Information
Business:

 

We are a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). Our solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform (StratX Platform), is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. We estimate our solution currently addresses approximately 500,000 patients in the United States and 700,000 patients in select international markets, which represents a global market opportunity of approximately $12 billion.

Industry: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Employees: 180
Founded: 1995
Contact Information
Address 700 Chesapeake Drive, Redwood City, CA 94063. US
Phone Number 1-650-364-0400
Web Address http://www.pulmonx.com
View Prospectus: Pulmonx
Financial Information
Market Cap
Revenues $32.6 mil (last 12 months)
Net Income $-20.7 mil (last 12 months)
IPO Profile
Symbol LUNG
Exchange NASDAQ
Shares (millions): 0.0
Price range $0.00 - $0.00
Est. $ Volume $86.3 mil
Manager / Joint Managers BofA Securities/ Morgan Stanley
CO-Managers Stifel/ Wells Fargo Securities/ Canaccord Genuity
Expected To Trade:
Status: Withdrawn
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change